Mountain View, California - Smartlens, a leading medical equipment manufacturing company specializing in innovative technologies for diagnosing and treating glaucoma, announced today the successful completion of its Series A funding round, raising an impressive $6.1 million. The funding round was led by Graphene Ventures, Boutique Venture Partners, Ambit Health Ventures, and 3E Bioventures Capital, solidifying Smartlens' position as a key player in the medical technology industry.

Glaucoma, a chronic eye disease and the leading cause of irreversible blindness has long posed challenges in diagnosis and treatment. Smartlens aims to address this significant unmet need with its breakthrough product, miLens. As a clinical-stage company, Smartlens has developed miLens, a non-invasive, contact lens-based device capable of monitoring intraocular pressure, which is the primary and only treatable risk factor for glaucoma.

Presenting clinical solid results at the highly regarded American Glaucoma Society 2023 meeting, Smartlens has demonstrated the effectiveness of miLens in revolutionizing glaucoma diagnosis and treatment. With plans to commercialize miLens in 2024, Smartlens is poised to make a lasting impact on the lives of countless individuals affected by glaucoma.

At the core of miLens is Smartlens' proprietary, electronics-free sensor technology, protected by a robust portfolio of patents spanning over 40 countries. This groundbreaking technology sets Smartlens apart in the industry, ensuring its position as a leader in glaucoma innovation. In addition, Smartlens is proud to own THERmic, an advanced non-invasive drug delivery technology that not only helps prevent disease progression but also enhances treatment effectiveness by offering personalized therapies for individual patients. This breakthrough paves the way for a new generation of medicines that address the complexities of glaucoma.

Founded by Savas Komban, Smartlens' commitment to excellence and innovation has garnered recognition from renowned institutions, venture capital firms, and key opinion leaders. Prominent investors, including Graphene Ventures, Boutique Venture Partners, Ambit Health Ventures, and 3E Bioventures Capital, have placed their confidence and support in Smartlens, recognizing the company's transformative potential in glaucoma. Additionally, partnerships with esteemed institutions like Stanford University have further solidified Smartlens' position as a frontrunner in medical technology.